Patents by Inventor Curzio Ruegg

Curzio Ruegg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Biomarker combinations for colorectal tumors
    Patent number: 10246748
    Abstract: The present invention relates to methods and kits for the detection of predetermined biomarkers for early diagnosis and management of cancer, and in particular, colorectal tumors.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: April 2, 2019
    Assignee: NOVIGENIX SA
    Inventors: Stavros Therianos, Curzio Ruegg, Sylvain Monnier-Benoit, Laura Ciarloni, Sahar Hosseinian
  • Biomarker Combinations for Colorectal Tumors
    Publication number: 20150299802
    Abstract: The present invention relates to methods and kits for the detection of predetermined biomarkers for early diagnosis and management of cancer, and in particular, colorectal tumors.
    Type: Application
    Filed: November 4, 2013
    Publication date: October 22, 2015
    Inventors: Stavros Therianos, Curzio Ruegg, Sylvian Monnier-Benoit, Laura Ciarloni, Sahar Hosseinian
  • Biomarker combinations for colorectal cancer
    Patent number: 8697350
    Abstract: The present invention relates to methods and kits for the detection of predetermined biomarkers for early diagnosis and management of cancer, and in particular, colorectal cancer.
    Type: Grant
    Filed: June 4, 2008
    Date of Patent: April 15, 2014
    Assignee: Diagnoplex
    Inventors: Curzio Ruegg, Sylvain Monnier-Benoit, Laura Ciarloni, Stavros Therianos
  • COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha
    Publication number: 20110177027
    Abstract: The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and tumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) or chemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone.
    Type: Application
    Filed: March 21, 2011
    Publication date: July 21, 2011
    Inventors: Matthias GRELL, Simon GOODMAN, Curzio RUEGG
  • BIOMARKDER COMBINATIONS FOR COLORECTAL CANCER
    Publication number: 20100330079
    Abstract: The present invention relates to methods and kits for the detection of predetermined biomarkers for early diagnosis and management of cancer, and in particular, colorectal cancer.
    Type: Application
    Filed: June 4, 2008
    Publication date: December 30, 2010
    Inventors: Curzio Ruegg, Sylvain Monnier-Benoit, Laura Ciarloni, Stavros Therianos
  • COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF alpha
    Publication number: 20090035270
    Abstract: The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and rumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) or chemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone.
    Type: Application
    Filed: September 4, 2007
    Publication date: February 5, 2009
    Inventors: Matthias Grell, Simon Goodman, Curzio Ruegg
  • Combination therapy using anti-angiogenic agents and tnf alpha
    Publication number: 20040136949
    Abstract: The invention relates to a combination therapy for the treatment of tumors metastases comprising administration of anti-angiogenic agents and tumor necrosis factor alpha (TNFa) optionally together with other cytotoxic agents, such as interferon gamma (IFNy) orchemotherapeutic agents such as anti-EGFR antibodies. The method and the pharmaceutical compositions comprising said agents can result in a synergistic potentiation of the tumor cell proliferation inhibition effect of each individual therapeutic agent, yielding more effective treatment than found by administering an individual component alone.
    Type: Application
    Filed: October 23, 2003
    Publication date: July 15, 2004
    Inventors: Matthias Grell, Simon Goodman, Curzio Ruegg